Cobactan Mc Intramammary Suspension 75 Mg Milking Cow
Revised: June 2014
AN: 00287/2014
Summary of product characteristics
NAME OF the VETERINARY MEDICINAL PRODUCT
Cobactan MC Intramammary Suspension 75 mg Milking Cow
QUALITATIVE AND QUANTITATIVE COMPOSITION
Per 8g syringe:
Active substance:
Cefquinome 75.0mg
(as cefquinome sulphate)
For full list of excipients, see section 6.1
PHARMACEUTICAL FORM
Intramammary Suspension
White to slightly yellow, oily viscous homogeneous intramammarysuspension
CLINICAL PARTICULARS
Target species
Lactating cows
Indications for use, specifying the target species
For the treatment of clinical mastitis in the lactating dairy cow caused by bacteria susceptible to cefquinome.
Contra-indications
Not to be administered to animals which are known to be hypersensitive to cephalosporin antibiotics.
There may be cross sensitivity to penicillins.
Special warning for each target species
None
Special precautions for use
Special precautions for use in animals
None
Special precautions to be taken by the person administering the medicinal product to the animals
When infusing heifers protective gloves should always be worn in order to avoid skin contact.
Penicillins and cephalosporins may cause hypersensitivity (allergy) following injection, inhalation, ingestion or skin contact. Hypersensitivity to penicillins may lead to cross sensitivity to cephalosporin and vice versa. Allergic reactions to these substances may occasionally be serious.
Do not handle this product if you know you are sensitised, or if you have been advised not to work which such preparations.
Handle this product with great care to avoid exposure, taking all recommended precautions.
If you develop symptoms following exposure, such as skin rash, you should seek medical advice and show the Doctor this warning. Swelling of the face, lips and eyes or difficulty in breathing are more serious symptoms and require urgent medical attention.
Wash hands after use.
Adverse reactions (frequency and seriousness)
None known
Use during pregnancy or lactation
The product is intended for use during lactation. No restrictions apply for use during pregnancy.
Interaction with other medicinal products and other forms of interaction
There is a cross sensitivity between the various cephalosporins.
Amounts to be administered and administration route
The contents of one syringe should be infused gently into the teat of the infected quarter every 12 hours after each of three successive milkings.
Milk out the affected quarter(s). After thoroughly cleaning and disinfecting the teat and teat orifice, gently infuse the contents of one syringe into each affected quarter. Disperse the product by gentle massage of the teat and udder of the affected animal.
Further Information:
Combined Therapy
For the treatment of E.colimastitis, experimental challenge studies have shown that the use of this product in combination with Cobactan 25 mg/ml suspension for injection leads to an improvement in efficacy, particularly in terms of bacterial cure rate.
For combined therapy the following treatment regime should be followed:
Cobactan 25 mg/ml |
Cobactan MC |
1mg cefquinome/kg bw (2ml/50 kg bw) 24 hours 1mg cefquinome/kg bw (2ml/50 kg bw) |
One syringe gently infused into the teat of the infected quarter 12 hours One syringe gently infused into the teat of the infected quarter 12 hours One syringe gently infused into the teat of the infected quarter |
Overdose (symptoms, emergency procedures, antidotes), if necessary
No symptoms expected or emergency procedures required.
Withdrawal periods
Meat and offal: 4 days
Milk: 5 days (120 hours)
When using Cobactan MC and Cobactan 25 mg/ml in combination, the withdrawal periods are as follows: Meat and offal: 5 days; Milk: 5 days (120 hours).
PHARMACOLOGICAL PROPERTIES
ATCvet Code:QJ51DA92
Pharmacotherapeutic group:antibacterials for intramammary use, Other β-lactam antibacterials for intramammary use, Cephalosporins and related substances.
Pharmacodynamic properties
Cefquinome is an antibacterial drug of the cephalosporin group which acts by inhibition of cell wall synthesis. It is characterised by its broad therapeutic spectrum of activity and a high stability against penicillinases and beta-lactamases.
Pharmacokinetic particulars
In vitro, Cefquinome has antibiotic activity against common Gram negative and Gram positive bacteria includingSalmonellaspp, Haemophilusspp, Pasteurellaspp,Klebsiella spp, Corynebacterium pyogenes, Escherichia coli, A.pleuropneumoniae, Proteus mirabilis, Staphylococcus aureus, Streptococcus dysgalactiae and Streptococcus uberis.
The product has been developed to treat clinical mastitis caused by sensitive strains of Staphylococcus aureus, Streptococcus uberis, Streptococcus dysgalactiae, Escherichia coli and other enterobacteria.
The base disperses readily in milk and allows rapid distribution of Cefquinome.
Cefquinome as a fourth generation cephalosporin combines high cellular penetration and ß-lactamase stability.In contrast to cephalosporins of previous generations, cefquinome is not hydrolysed by chromosomally–encoded cephalosporinases of the Amp-C type or by plasmid mediated cephalosporinases of some enterobacterial species. However, some Extended Spectrum beta-lactamases (ESBL) can hydrolyse cefquinome and cephalosporins of other generations. The potential for resistance development against cefquinome is rather low. High-level resistance to cefquinome would require the coincidence of two genetic modifications, i.e. hyperproduction of specific ß-lactamases as well as decreased membrane permeability.
PHARMACEUTICAL PARTICULARS
List of excipients
White soft paraffin
Liquid paraffin
Incompatibilities
None known
Shelf life
Shelf life of the veterinary medicinal product as packaged for sale: 30 months
Special precautions for storage
Do not store above 25°C
The syringe must only be used once. Part used syringes should be discarded.
Nature and composition of immediate packaging
White opaque polyethylene syringe containing 75mg cefquinome in packs of 3, 15, 20, 24 and 30 syringes.
Not all presentations may be marketed.
Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products, if appropriate
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
MARKETING AUTHORISATION HOLDER
Intervet UK Ltd.
Walton Manor
Walton
Milton Keynes
Buckinghamshire
MK7 7AJ
MARKETING AUTHORISATION Number
Vm:01708/4444
DATE OF FIRST AUTHORISATION
Date:29 May 1997
DATE OF REVISION OF TEXT
Date:June 2014
03 June 2014
Page 10 of 10